🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

LAG3 Expression in Triple Negative Breast Cancer

RecruitingNAAges any - anyFemaleSamsung Medical Center
NCT06259162 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This study is the experimental study for relationship between LAG-3 expression / immue checkpoint protein expression and neoadjuvant chemotherapy plus immune checkpoint inhibitor in triple negative breast cancer.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Planned neoadjuvant chemotherapy * Triple negative breast cancer Exclusion Criteria: * HER2-positive breast cancer * Hormone receptor positive breast cancer
💊

What it tests

  • LAG-3 expression / immune checkpoint protein expression
📍

Where

1 site
Ji-Yeon Kim
Seoul, South Korea
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy